| Company Name: |
Twochem Co.Ltd. |
| Tel: |
021-58111628 15800915896 |
| Email: |
sales@twochem.com |
PBI-4050 Sodium salt manufacturers
- Fezagepras sodium
-
- $36.00
-
2026-07-15
- CAS:1254472-97-3
- Purity: 99.59%
- Supply Ability: 10g
- Fezagepras sodium
-
- $36.00
-
2026-07-15
- CAS:1254472-97-3
- Purity: 99.59%
- Supply Ability: 10g
|
| | PBI-4050 Sodium salt Basic information |
| | PBI-4050 Sodium salt Chemical Properties |
| storage temp. | Store at -20°C | | solubility | Water : ≥ 100 mg/mL (438.10 mM);DMSO : ≥ 64 mg/mL (280.38 mM) | | form | Solid | | color | White to off-white |
| | PBI-4050 Sodium salt Usage And Synthesis |
| Uses | Fezagepras (Setogepram) sodium acts as an orally active agonist for GPR40 and as an antagonist or inverse agonist for GPR84[1]. Fezagepras sodium decreases renal, liver and pancreatic fibrosis[1][2]. Fezagepras sodium exerts anti-fibrotic, anti-inflammatory and anti-proliferative actions[2]. | | in vivo | Fezagepras sodium (100 mg/kg/day; gavage from 8-20 weeks of age) markedly decreases hyperglycemia and markedly improvea glucose tolerance in type 2 diabetes eNOS-/-db/db mice[1].· | Animal Model: | Type 2 diabetes eNOS-/-db/db mice[1] | | Dosage: | 100 mg/kg/day | | Administration: | Given via daily gavage from 8-20 weeks | | Result: | Compared with vehicle-treated mice, hyperglycemia was markedly decreased, and glucose tolerance was markedly improved. |
| | References | [1] Li Y, et al. Fatty acid receptor modulator PBI-4050 inhibits kidney fibrosis and improves glycemic control. JCI Insight. 2018 May 17;3(10). pii: 120365. DOI:10.1172/jci.insight.120365
[2] Grouix B, et al. PBI-4050 Reduces Stellate Cell Activation and Liver Fibrosis through Modulation of Intracellular ATP Levels and the Liver Kinase B1/AMP-Activated Protein Kinase/Mammalian Target of Rapamycin Pathway. J Pharmacol Exp Ther. 2018 Oct;367(1):71-81. DOI:10.1124/jpet.118.250068 |
| | PBI-4050 Sodium salt Preparation Products And Raw materials |
|